AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day
November 18 2009 - 8:00AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced that Patrick Iversen, Ph.D., Senior Vice President
of Strategic Alliances, will present at the upcoming
Transformational Medical Technologies Initiative (TMTI) Industry
Day taking place in Dallas, Texas.
Dr. Iversen will present on Thursday, Nov. 19, as part of a
"Performers Panel" in which a panel of current TMTI performers from
academia, biotechnology companies and large pharmaceutical firms
will provide their perspectives on lessons learned from their
experiences, timeframes and what was required in order to
effectively do business with the TMTI.
The Transformational Medical Technologies Initiative (TMTI)
Industry Day is being held as an ancillary workshop during the
Chemical and Biological Defense Science and Technology (CBD
S&T) Conference. TMTI Industry Day brings together
professionals from government, academia, and the biotechnology and
pharmaceutical industries to learn about TMTI and discuss
collaborative opportunities with the program, the current state of
medical countermeasure preparedness, and plans for enhancing
national capabilities to respond to emerging and novel biological
threats.
AVI's RNA-based drugs against biological threats, including
influenza, Ebola, Marburg and Junin viruses, are being supported by
contract funding from the Defense Threat Reduction Agency's (DTRA)
Transformational Medical Technologies Initiative (TMTI) and carried
out in collaboration with the U.S. Army Medical Research Institute
of Infectious Diseases (USAMRIID). The majority of the
collaborative research effort between AVI and USAMRIID has been
supported by a research contract from the DoD's TMTI with the goal
of developing a new antiviral platform targeting hemorrhagic fever
viruses.
About DTRA & TMTI
DTRA was founded in 1998 to integrate and focus the capabilities
of the DoD that combat the weapons of mass destruction (WMD)
threat. The mission of the DTRA is to safeguard America and its
allies from WMD (e.g. chemical, biological, radiological, nuclear,
and high yield explosives) by providing capabilities to reduce,
eliminate, and counter the threat, and thereby mitigate its
effects. Under DTRA, DoD resources, expertise and capabilities are
combined to ensure the United States remains ready and able to
address the present and future WMD threats.
The TMTI was created by the DoD to protect the Warfighter from
emerging and genetically altered biological threats by discovering
and developing a wide range of medical countermeasures through
enhanced medical research, development, test and evaluation
programs. The TMTI Program Office is matrixed from the Joint
Science and Technology Office -- DTRA and Joint Program Executive
Office -- Chemical and Biological Defense, with oversight from the
Office of the Secretary of Defense. For more information on TMTI,
visit http://www.tmti-cbdefense.org.
About USAMRIID
USAMRIID, located at Fort Detrick, Maryland, is the lead medical
research laboratory for the U.S. DoD Biological Defense Research
Program. The Institute conducts basic and applied research on
biological threats resulting in medical solutions (such as
vaccines, drugs and diagnostics) to protect the Warfighter. While
USAMRIID's primary mission is focused on the military, its research
often has applications that benefit society as a whole. USAMRIID is
a subordinate laboratory of the U.S. Army Medical Research and
Materiel Command. For more information, visit
www.usamriid.army.mil.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
RNA-based drugs utilizing proprietary derivatives of its antisense
chemistry (morpholino-modified phosphorodiamidate oligomers or
PMOs) that can be applied to a wide range of diseases and genetic
disorders through several distinct mechanisms of action. Unlike
other RNA therapeutic approaches, AVI's antisense technology has
been used to directly target both messenger RNA (mRNA) and its
precursor (pre-mRNA), allowing for both up- and down-regulation of
targeted genes and proteins. AVI's RNA-based drug programs are
being evaluated for the treatment of Duchenne muscular dystrophy,
including an ongoing systemic Phase 1b/2 clinical trial of exon
skipping AVI-4658. AVI's antiviral programs have demonstrated
promising outcomes in Ebola Zaire and Marburg Musoke virus
infections and may prove applicable to other viral targets such as
Junin, influenza, HCV or Dengue viruses. For more information,
visit www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
AVI Press and Investor Contact: Julie Rathbun Investor Relations
(541) 224-2575 Investorrelations@avibio.com
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024